We evaluated the participatory role of human HLA-DR molecules in control of virus from the central nervous system and in the development of subsequent spinal cord demyelination. The experiments utilized intracranial infection with Theiler's murine encephalomyelitis virus (TMEV), a picornavirus that, in some strains of mice, results in primary demyelination. We studied DR2 and DR3 transgenic mice that were bred onto a combined class I-deficient mouse (beta-2 microglobulin deficient; ␤2m 
We evaluated the participatory role of human HLA-DR molecules in control of virus from the central nervous system and in the development of subsequent spinal cord demyelination. The experiments utilized intracranial infection with Theiler's murine encephalomyelitis virus (TMEV), a picornavirus that, in some strains of mice, results in primary demyelination. We studied DR2 and DR3 transgenic mice that were bred onto a combined class I-deficient mouse (beta-2 microglobulin deficient; ␤2m An important question in neurovirology and neuroimmunology is how virus infections are controlled in the central nervous system. This question is particularly important when viruses persist in the brain or spinal cord but are cleared from the tissues outside the central nervous system (CNS). There is evidence that specific aspects of the immune system clear specific classes of viruses. For example, antibody may be critically important for virus control in the CNS in certain arbovirus infections (9) . In contrast, arenaviruses, such as lymphocytic choriomeningitis virus, require class I-restricted cytotoxic lymphocytes to eliminate intracerebral infection (50) . Cytotoxicity may not be necessary for virus control by lymphocytes. Instead, the factors secreted by cells in the inflammatory infiltrate may control virus infection in neurons and other CNS cells. Gamma interferon (IFN-␥) has been shown in several model systems to be essential for virus control in the CNS (27, 46, 48) . Other cytokines such as interleukin-6 (IL-6) may also help protect neurons from virus injury (35) . Natural killer cells have also been shown to be critical in preventing fulminant virus-induced encephalitis (37) .
Most of the investigative work on controlling CNS virus infection has been done in rodents. Little data exist about the human immune factors contributing to this process. In an attempt to approach this difficult problem, we created a series of human HLA transgenic mice. We originally created class II A␤ 0 mice without endogenous CD4 ϩ T-cell-dependent immune responses. We then substituted the human class II gene (DR2 or DR3) for the mouse class II response. These mice mount normal class II-restricted CD4 T-cell-mediated immune responses to a number of antigens and infectious agents, (5, 14, 23, 34) and have an intact mouse CD8 ϩ T-cell-restricted endogenous class I major histocompatibility complex (MHC) immune response. Therefore, we could not exclude the contribution of the endogenous mouse MHC class I response to antigen challenge. We mated the A␤ 0 .DR transgenic mice to beta-2 microglobulin-deficient mice (␤2m 0 ) and generated lines of mice deficient in both the mouse endogenous class I and class II immune responses. Thus, responses observed in these mice would be uniquely the consequence of the human class II gene.
We tested these mice with a naturally occurring viral pathogen of the CNS. Our laboratory has investigated virus control, virus persistence, and demyelination following intracerebral injection of Theiler's murine encephalomyelitis virus (TMEV), a picornavirus that induces a characteristic biphasic disease in the CNS of immune competent mice (3, 21) . During the first 10 to 12 days of infection, the virus replicates primarily in neurons of the hippocampus, striatum, cortex of the brain, and anterior horn cells of the spinal cord and then clears rapidly from these cells irrespective of MHC haplotype. Oligodendrocytes and macrophages are also infected early (31 , and C57BL/6 (black) mice as controls. Littermate controls for these mice are described in the text. For a positive control mouse strain that develops chronic demyelination, we used B10.Q H-2 q mice. We chose this strain as a positive control because it shares the same C57BL (black) background as the other mice in the experiment. Experiments were approved by the Mayo IACUC and conformed to guidelines for the care of animals by the National Institutes of Health. Mice were followed daily until they were moribund or died. Mice that survived the acute infection were sacrificed on day 45 (endpoint of the study) after infection for pathology and virus RNA expression. Some of the data include A␤ 0 .␤2m 0 .DR4 mice. However, the data on these mice are limited because they were difficult to breed.
Infection and harvesting of the CNS for morphology. At 4 to 6 weeks of age, mice were intracerebrally infected with 2 ϫ 10 5 PFU of TMEV in a total volume of 10 l. At various times after infection, mice were perfused via intracardiac puncture with 50 ml of Trump's fixative. Spinal cords and brains were removed and postfixed for 24 to 48 h in Trump's fixative in preparation for morphological analysis.
Spinal cord morphometry. Spinal cords were cut into 1-mm coronal blocks. Every third block was osmicated and embedded in glycol methacrylate. Twomicrometer sections were prepared and stained with a modified erichrome/cresyl violet stain (38) . Morphological analysis was performed on 12 to 15 sections per mouse as previously described (43) . Each quadrant from every coronal section from each mouse was graded for the presence or absence of gray matter disease, meningeal inflammation, and demyelination. The score was expressed as the percentage of spinal cord quadrants examined with the pathological abnormality. A maximum score of 100 indicated a particular pathological abnormality in every quadrant of all spinal cord sections of a given mouse. All grading was performed without knowledge of the experimental group. Additional spinal cord blocks were embedded in paraffin for immunocytochemistry.
Brain pathology. Brain pathology was assessed at days 18 and 45 postinfection, using our previously described technique (35) . Following perfusion with Trump's fixative, we made two coronal cuts in the intact brain at the time of removal from the skull (one section through the optic chiasm and a second section through the infundibulum). As a guide, we used the Atlas of the Mouse Brain and Spinal Cord corresponding to sections 220 and 350, page 6 (51). This resulted in three blocks that were then embedded in paraffin. This allowed for systematic analysis of the pathology of the cortex, corpus callosum, hippocampus, brain stem, striatum, and cerebellum. The resulting slides were then stained with hematoxylin and eosin. Pathological scores were assigned without knowledge of experimental group to the following areas of the brain: cortex, corpus callosum, hippocampus, brainstem, striatum, and cerebellum. Each area of the brain was graded on a fourpoint scale as follows: 0, no pathology; 1, no tissue destruction but only minimal inflammation; 2, early tissue destruction (loss of architecture) and moderate inflammation; 3, definite tissue destruction (demyelination, parenchymal damage, cell death, neurophagia, neuronal vacuolation); and 4, necrosis (complete loss of all tissue elements with associated cellular debris). Meningeal inflammation was assessed and graded as follows: 0, no inflammation; 1, one cell layer of inflammation; 2, two cell layers of inflammation; 3, three cell layers of inflammation; 4, four or more cell layers of inflammation. The area with the maximal extent of tissue damage was used for assessment of each brain region.
Immune staining for virus antigen. Immunocytochemistry was performed on paraffin-embedded sections as previously described (35) . Slides were deparaffinized in xylene and rehydrated through an ethanol series (absolute, 95%, 70%, and 50%). Virus antigen staining was carried out using polyclonal antisera to TMEV DA (45) , which reacts strongly with the capsid proteins of TMEV. Following incubation with a secondary biotinylated antibody (Vector Laboratories, Burlingame, CA), immunoreactivity was detected using the avidin-biotin immunoperoxidase technique (Vector Laboratories). The reaction was developed using Hanker-Yates reagent with hydrogen peroxide as the substrate (Polysciences, Warrington, PA). Slides were lightly counterstained with Mayer's hematoxylin. We examined the distribution of virus antigen in the spinal cords of B6, ␤2m RNA isolation. We removed the brain and spinal cords from animals infected with TMEV. Total RNA was extracted from brain and spinal cord (48) . Briefly, the tissues were frozen and stored in liquid nitrogen. Tissue samples were homogenized in the RNA STAT-60 (1 ml/100 mg tissue) (Tel-Test, Inc., Friendswood, TX), and total RNA was isolated according to the manufacturer's recommendations. The RNA concentrations were determined by spectrophotometer. The RNA samples were equilibrated to a concentration of 0.25 g/l and stored at Ϫ80°C.
RT-PCR and real-time analysis for virus RNA. We used the VP2 fragment of TMEV, a viral capsid region of DA virus, for reverse transcription-PCR (RT-PCR) (48) . The primer pair sequences for VP2 of DA virus were as follows: 5Ј-TGGTCGACTCTGTGGTTACG-3Ј (forward) and 5Ј-GCCGGTCTTGCAA AGATAGT-3Ј (reverse). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control for intersample variability. The sequences used for assaying the presence of GAPDH were as follows: 5Ј-ACCACCATGGAGAAGGC-3Ј (forward) and 5Ј-GGCATGGACTGTGGTCATGA-3Ј (reverse). The sizes of PCR products amplified with primers were 238 bp for VP2 and 236 bp for GAPDH.
Standards were generated by serial 10-fold dilutions of plasmid cDNA. Standards were amplified in parallel with unknown samples by real-time quantitative RT-PCR using the LightCycler (Roche, Indianapolis, IN) as per the manufacturer's instructions.
Quantification of cytokine RNA from the brain by real-time RT-PCR. The primer sequences for each gene were as follows: GAPDH forward, 5Ј-AGCTT GTCATCAACGGGAAG-3Ј, and reverse, 5Ј-TTTGATGTTAGTGGGGTCTC G-3Ј; IL-2 forward, 5Ј-GCTGTTGATGGACCTACAGGA-3Ј, and reverse, 5Ј-ATCCTGGGGAGTTTCAGGTT-3Ј; IL-4 forward, 5Ј-CATCGGCATTTTGA ACGAG-3Ј, and reverse, 5Ј-ACGTTTGGCACATCCATCTC-3Ј; IL-6 forward, 5Ј-GCTACCAAACTGGATATAATCAGGA-3Ј, and reverse, 5Ј-CCAGGTAG CTATGGTACTCCAGAA-3Ј; IL-10 forward, 5Ј-ACTGCACCCACTTCCCAG T-3Ј, and reverse, 5Ј-TGTCCAGCTGGTCCTTTGTT-3Ј; IFN-␥ forward, 5Ј-T CTGGAGGAACTGGCAAAAG-3Ј, and reverse, 5Ј-TTCAAGACTTCAAAG AGTCTGAGG-3Ј; and tumor necrosis factor (TNF), forward, 5Ј-CTGTAGCC CACGTCGTAGC-3Ј, and reverse, 5Ј-TTGAGATCCATGCCGTTG-3Ј. Percent expression relative to control GAPDH was calculated using the equation: % expression ϭ {[1.9ˆ(average crossing point of experimental gene for control group Ϫ crossing point of experimental gene for each sample)]/[1.9ˆ(average crossing point of GAPDH in the control group Ϫ crossing point of GAPDH for each sample)]} ϫ 100.
Virus-specific antibody isotype ELISA. Sera were isolated and stored at Ϫ80°C. Total serum immunoglobulin Gs (IgGs) against TMEV were assessed by enzyme-linked immunosorbent assay (ELISA) as described previously (32) . Purified virus was adsorbed to 96-well plates (Immulon II; Dynatech Laboratories Inc., Chantilly, VA) and then blocked with 1.0% bovine serum albumin (BSA; Sigma Chemical Co. St. Louis, MO) in phosphate-buffered saline. Serial serum dilutions were made in 0.2% BSA-phosphate-buffered saline and added in triplicate. Biotinylated anti-mouse IgG secondary antibodies were used for detection (Jackson Immunoresearch Labs, Westbury, NY). Signals were amplified with streptavidin-labeled alkaline-phosphatase (Jackson Immunoresearch Labs) and detected using p-nitrophenyl phosphate as the substrate. Absorbances were read at 405 nm and plotted against serum dilution factors. In addition, virus neutralization assays were performed to determine the serum concentration necessary to neutralize 90% of infectious virus by plaque assay on L2 cells.
Isolation of BILs.
Brains from virus-infected mice were homogenized in 1 ml of RPMI 1640 and centrifuged in a 30% Percoll gradient at 10,000 rpm for 30 min at 4°C. Brain-infiltrating lymphocytes (BILs) at the bottom of the gradient were washed in RPMI by centrifugation at 1,500 rpm for 5 min at 4°C. BILs were resuspended in RPMI and depleted of red blood cells with a hypotonic solution and washed again to use in flow cytometry analysis.
Flow cytometry analysis. BILs were incubated in 50 l of fluorescence-activated cell sorter (FACS) medium (1% BSA and 0.02% sodium azide in Hanks' balanced salt solution) with anti-CD8a-fluorescein isothiocyanate (clone 53-6.7) and anti-CD4-phycoerythrin (clone H129.19) antibodies. BILs were washed three times in FACS medium and fixed in 2% paraformaldehyde. For evaluation of T-cell activation marker CD69, BILs were blocked for Fc receptor in 100 l of medium from the 2.4G 2 hybridoma. After blocking for 30 min, anti-CD45-allophycocyanin, CD4-phycoerythrin, and either CD69-fluorescein isothiocyanate or isotype control antibodies were added and incubated for 1 h on ice. BILs were washed two times in FACS medium and fixed in 2% paraformaldehyde. Flow cytometry was performed using a FACSCalibur flow cytometer (Becton Dickinson, San Diego, CA). Data were analyzed using WinMDI. Dead cells were excluded based on the forward scatter profile.
Statistics. Data were analyzed using either the Student's t test for normally distributed data or the Mann-Whitney rank sum test for data not normally distributed. Analysis of variance (ANOVA) was used for comparisons of more than one group. The Tukey or Dunn's test was used for all pairwise multiple comparison procedures. Proportional data were evaluated using the Z-test. The level for significance was set as P Ͻ 0.05 for all tests.
RESULTS
Transgenic expression of human class II HLA-DR prevents death in TMEV-infected A␤ 0 .␤2m 0 mice. Twenty-seven A␤ 0 . ␤2m 0 mice were infected with TMEV, and all died or were moribund by 18 days postinfection. However, both ␤ 2 -microglobulin and class II-deficient mice had minimal neurologic deficits and survived past the 18-day time point, demonstrating that MHC class I and MHC class II can independently protect mice from early neurologic disease. Both A␤.␤2m 0 .DR2 (n ϭ 42) and A␤ 0 .␤2m 0 .DR3 (n ϭ 19) mice infected with TMEV survived past the 18-day time point without neurologic deficits. Thus, expression of human class II genes alone prevented the death of A␤ 0 .␤2m 0 mice following a lethal dose of TMEV. Expression of human class II MHC transgenes prevents severe neuronal gray matter disease observed in the spinal cord of TMEV-infected A␤ 0 .␤2m 0 mice at 18 days postinfection. We calculated the percentage of spinal quadrants with neuronal injury in the gray matter disease, demyelination in the white matter, and inflammation in the white matter (Table  1 ; n ϭ number of mice). We noted severe gray matter disease in the spinal cord of A␤ 0 .␤2m 0 mice. Gray matter disease was characterized by neuronal loss, intense inflammation around anterior horn cells, and vacuolar degeneration of neurons ( 
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on November 1, 2017 by guest http://jvi.asm.org/ or DR3 transgenic mice compared to A␤ 0 .␤2m 0 mice was statistically significant (ANOVA on ranks, P Ͻ 0.001). Similarly low levels of gray matter disease were observed in ␤2m 0 mice and in A␤ 0 mice. Mild white matter inflammation was observed in A␤ 0 .␤2m 0 and ␤2m 0 mice, whereas essentially none was observed in DR2 or DR3 mice. Susceptible strains of B10.Q and SJL mice showed minimal gray matter disease, but, as expected, showed white matter inflammation and demyelination. Thus, expression of DR molecules was able to control the early gray matter disease observed in A␤ 0 .␤2m 0 mice. Expression of DR transgene protects mice from spinal cord demyelination. We asked whether the expression of these human genes would influence chronic demyelination at 45 days following infection (Table 2 and Fig. 2 ). A␤ 0 .␤2m 0 mice were not available for these analyses, since none survived to this time point. A␤ 0 .␤2m 0 .DR2 and A␤ 0 .␤2m 0 .DR3 mice showed essentially no demyelination in the spinal cord following virus infection ( Fig. 2 and Table 2 ). There was a significant decrease in quadrants showing demyelination in A␤ 0 .␤2m 0 .DR2 or A␤ 0 .␤2m 0 .DR3 mice compared to ␤2m 0 mice (P Ͻ 0.001). Our comparison with another DR allele, in A␤ 0 .␤2m 0 .DR4 (n ϭ 4) mice infected with TMEV, revealed no demyelination in any of 156 quadrants examined. In contrast, both ␤2m 0 mice (43) and A␤ 0 mice (32) showed low levels of demyelination in the spinal cord white matter. As expected, immunocompetent B6 mice (n ϭ 11) showed no demyelination. Positive control B10.Q and SJL mice showed demyelination at this time point (Table 2) .
Of the multiple littermate controls injected with TMEV to exclude for any other unknown genetic difference besides DR alleles, the following mice, as expected, did not show demyelination in the spinal cord at 45 days following Theiler's infection: Expressions of DR2 or DR3 transgenes protect A␤ 0 .␤2m 0 mice from encephalitis following TMEV infection. We asked whether expression of DR2 or DR3 protected specific populations of brain cells from injury (Fig. 3) . Analyzing the brain pathology at 18 days after infection (the time frame when A␤ 0 .␤2m 0 mice die) and using a semiquantitative four-point scale for analysis, we noted pathology in all strains (B6, ␤2m 0 , A␤ 0 , A␤ 0 .␤2m 0 , A␤ 0 .␤2m 0 .DR2, and A␤ 0 .␤2m 0 .DR3) in the cortex, hippocampus, striatum, and corpus callosum, whereas there was no or minimal disease in the cerebellum (Fig. 3) . Levels of meningeal inflammation were similar between the As expected, B6 mice resolved brain disease when comparing the pathology at 7 days (2.000 Ϯ 0.150; n ϭ 119), 21 days (1.321 Ϯ 0.141; n ϭ 140), and 45 days (0.325 Ϯ 0.086; n ϭ 126). In contrast, in the ␤2m 0 strain, brain pathology persisted when comparing the results at 7 days (1.929 Ϯ 0.249; n ϭ 56), 21 days (1.029 Ϯ 0.186; n ϭ 70), and 45 days (1.071 Ϯ 0.195; n ϭ 56). There was a statistical difference in the increase in brain pathological scores comparing ␤2m 0 mice (n ϭ 56) to B6 mice (P Ͻ 0.001, Mann-Whitney rank sum test). There was no statistical difference in the brain scores comparing B6 to A␤ 0 mice. DR2 and DR3 transgenic mice have minimal virus antigen in the spinal cord during the late stages of disease. We concentrated our analysis on the gray matter of the spinal cord at 18 days after infection to evaluate the association of virus antigen with early death (Fig. 4) We then analyzed the percentage of spinal cord quadrants with virus antigen in the white matter at the 45-day time point (Fig. 4) . A␤ 0 .␤2m 0 .DR3 mice (3.8 Ϯ 2.0; n ϭ 5) had minimal virus antigen in the white matter. There was a statistically significant decrease of virus antigen in the spinal white matter when comparing A␤ 0 .␤2m 0 .DR3 to ␤2m 0 mice (P ϭ 0.032). B6 mice, as expected, controlled virus infection and showed no antigen-positive cells in the spinal cord white matter. In contrast, both A␤ 0 and ␤2m 0 mice showed virus antigen in the white matter.
Levels of TMEV RNA in the brain and spinal cord at 7, 18, and 45 days following infection. Reports indicate that viral RNA persists following TMEV infection during chronic disease, even though it is difficult to detect infectious virus by plaque assay (53) . We tested the hypothesis that control of virus RNA lessened CNS pathology in A␤ 0 .␤2m 0 .DR3 mice (Fig. 5) . We controlled all experiments for expression of GAPDH RNA, which was consistent among strains. The level of GAPDH RNA in the brain was log 10 7.40 Ϯ 0.03 virus copies, and that in the spinal cords was log 10 
The humoral immune response to virus antigens does not explain the control of virus infection in DR transgenic mice.
To test whether the difference in phenotype between A␤ 0 .␤2m 0 mice (early virus replication and death) and A␤ 0 .␤2m 0 .DR2 mice or A␤ 0 .␤2m 0 .DR3 mice (virus control and minimal demyelination) resulted from differences in the humoral response to virus, we assessed serum IgG and IgM antibody responses by ELISA directed against purified virus antigens (Fig. 6) (Fig. 7 ). There were fewer CD4 ϩ T cells in the brain infiltrates of A␤ 0 .␤2m 0 .DR3 mice than in ␤2m 0 mice (Fig. 7) . None of the A␤ 0 .␤2m 0 .DR3 or ␤2m 0 mice had CD8 ϩ T cells in the brain infiltrate. The data indicate that the control of virus infection in A␤ 0 .␤2m 0 .DR3 mice probably depends on CD4 ϩ T cells. These cells may have acted alone or, more likely, in concert with other cells (macrophages, microglia, and astrocytes) to control virus infection and prevent chronic demyelination.
Cytokine expression in the brain of DR transgenic mice may explain the mechanism of control in virus infection. Cytokine analysis from 7-day-infected mice ( Fig. 8) showed both B6 and A␤ 0 .␤2m 0 .DR3 mice to have significantly higher IFN-␥ levels than A␤ 0 .␤2m 0 mice (P Ͻ 0.001). The DR3 transgenic mice also showed a significant increase in IL-2 transcripts compared to A␤ 0 .␤2m 0 mice (P Ͻ 0.05), which was similar to that observed in B6 mice. IL-4 was increased in B6 mice compared to A␤ 0 .␤2m 0 mice (P Ͻ 0.05). However, levels of IL-4 transcripts in DR3 transgenic mice were closer to values in A␤ 0 .␤2m 0 mice. By day 18, expression levels of IFN-␥ and IL-2 in both B6 and DR3 mice were reduced to the levels seen in the A␤ 0 .␤2m 0 mice (Fig. 8 ), which correlate with the reduced levels of virus RNA seen in the brains of both strains at this time. At 18 days, there was an increase in IL-6 (P Ͻ 0.001) and TNF-␣ (P Ͻ0.05) in the brains of A␤ 0 .␤2m 0 mice compared to B6 and DR3 transgenic mice. The data support the hypothesis that activated CD4 cells infiltrating the brain of A␤ 0 .␤2m 0 .DR3 mice at 7 days expressed the cytokines IFN-␥ and IL-2 to control virus infection. The increased expression of IL-6 and TNF-␣ in brains of A␤ 0 .␤2m 0 mice supports the possibility that these cytokines contribute to the severe pathology and death ob- Infection with Theiler's virus in most mouse strains studied to date usually results in two distinct phenotypes. In animals that do not develop demyelination, such as prototypic C57BL/6 mice, virus replicates in the brain during the first 7 to 10 days of infection, resulting in encephalitis involving the hippocampus, striatum, and cortex. The virus then clears rapidly from the brain following an intense inflammatory response (19) that precludes virus antigen expression and subsequent demyelination in the spinal cord. This protective response has been mapped genetically to H-2D genes by recombinant inbred strains (44) or with transgenic mice (42) . In resistant mice, the CD8 ϩ T-cell response is directed against an immunodominant viral peptide on VP2 that participates in virus clearance (1, 4, 12, 18, 26) Other investigators have studied Theiler's infection in BALB/c mice and have shown that CD8 ϩ T cells play a protective role, possibly as suppressor cells (10, 29) . In animals that develop demyelination, such as the prototypic SJL/J or B10.Q mice, similar early encephalitis occurs in the brain. However, in these mice, the virus antigen persists in glial cells and macrophages of the spinal cord after it clears from the brain. In susceptible mice, activated cytotoxic T cells are generated in the brain (20) without apparent viral or myelin specificity (17) . Demyelination in association with an intense inflammatory response, which begins in the spinal cord around day 21 following infection, is well established by day 45. Demyelination continues to worsen until 100 days after infection but then reaches a plateau (24) . However, the animals continue to worsen neurologically for another subsequent 100 days after infection as a result of loss of large-diameter axons from the spinal cord (24) .
This set of experiments with DR2 and DR3 transgenic mice challenges the model proposed by our lab and others that class I-restricted cytotoxic T lymphocytes are absolutely required for viral control of TMEV infection. DR transgenic mice showed CD4 ϩ T cells but not CD8 ϩ T cells. The CD4 ϩ cells in the brain were activated to an unknown antigen, since they expressed CD69 on their surface (56) (57) (58) . Thus, the DR2 or DR3 molecule by itself was able to protect from chronic demyelination. This is supported by previous data that indicate a critical role of CD4 T cells in clearance (13, 16, 47) . However, in the previous situations, it was not possible to determine if CD4 T cells alone contributed to this response, since these mice had functional CD8 T-cell compartments.
Previous studies have demonstrated that class I-deficient mice (␤2m 0 ) (7, 39) We do not know the precise mechanisms by which the DR2 or DR3 molecule by itself provides complete protection from chronic virus disease. Our laboratory is exploring several possibilities and has made significant progress in excluding the following. (i) Expression of human DR2 or DR3 may have resulted in the generation of class II-restricted cytotoxic lymphocytes against the virus. Class II-restricted cytotoxic lymphocytes restricted to human DR or DQ have been described in some other model systems (6, 22, 30, 59 ). However their presence is rare. We show in this paper that CD4 cells are activated, since they express the CD69 antigen. (ii) Expression of DR molecules may have generated CD4
ϩ T cells that recognize viral peptides and secreted protective molecules to limit virus infection and prevent neuronal injury. The Theiler's model system provides possible evidence that IFN-␥ (27, 40, 46) , , and TNF (36) are immune response-induced factors critical in controlling virus infection. We show in this paper that the DR transgenic mice secrete IFN-␥ and IL-2 early in infection, which may contribute to virus replication control. (iii) DR-restricted CD4 ϩ T cells may help B cells to secrete protective and neutralizing antibody to help control the virus infection. However, TMEV-infected A␤ 0 .␤2m 0 .DR2 or A␤ 0 .␤2m 0 .DR3 mice do not develop strong antibody-neutralizing titers to TMEV. (iv) DR molecules on macrophages or dendritic cells may function independently of T cells to promote virus control. This seems unlikely because CD4 T cells were activated in the lesion and were the predominant cell type in the infiltrate.
There are some precedents for human DR molecules influencing the course of Theiler's infection in animals. Transgenic expression of DR3 molecules in mice of a susceptible B10.M (H-2 f ) haplotype developed less demyelination than littermate controls without the DR3 transgene (5) . These experiments differed from the present experiments in that the parental mice were immune competent and of a haplotype that develops demyelination. In the B10M.DR3 experiments, we could not exclude the DR3 transgene from interacting with the mouse immune system (for example, generation of a more robust mouse class I immune response) to account for the reduction of demyelination. Nevertheless, the protective qualities of DR3 discovered in previous experiments support the current findings.
There are precedents for human DR molecules influencing the course of virus, parasite, or spirochete infection in humans. Human cytomegalovirus protein pp65 has been shown to down-regulate HLA-DR induction by causing DR accumulations in lysosomes with subsequent destruction of the HLA-DR alpha chain (33) . MHC class II allele (DRB1*1302) is associated with clearance of hepatitis B virus in The Gambia. In the infection with hepatitis C, DRB*0101-DQB1*0501 is associated with viral clearance, whereas DRB1*03011-DQB1*0201 is associated with chronic infection. Racial differences in the HLA class II association with hepatitis C virus may contribute to outcomes (52) . DRB1*01 and DRB1*017(03) have been associated with acute disseminated encephalomyelitis in children, a disease in which an autoimmune reaction occurs in the CNS as a result of a viral trigger (11) . In visceral leishmaniasis, HLA-DR2 is protective (25) . In contrast, prominent MHC class II associations have not been observed in another parasitic infection, malaria (54) . In spirochete infection resulting in Lyme's disease, HLA-DR7 allele is associated with highest antibody production against Borrelia burgdorferi (55) .
Even though strong epidemiological data associate human MHC haplotype with the outcome to infectious disease, it has not been possible to prove conclusively that a human class II gene alone influences the consequences of infection. This is because human HLA is a complex haplotype, and there is linkage disequilibrium between alleles. Because our studies used transgenic mice with a single human class II transgene without either the mouse endogenous class I or class II response, we are in a stronger position to conclude that molecules within the class II MHC complex directly influence the course of a viral infection in vivo.
